Business
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced plans to provide clinical data updates, including its intent to host two virtual investor conference calls and webcasts in January 2022 to discuss preliminary clinical data for TSHA-101 in GM2 gangliosidosis and high dose cohort and long-term clinical data for TSHA-120 in giant axonal neuropathy (GAN) from the respective ongoing Phase 1/2 trials.\n\nTaysha will host two separate conference calls and webcasts in January 2022 with the following agenda topics:\n\nTSHA-101 in GM2 gangliosidosis\n\n\nPreliminary clinical safety data and Hex A enzyme activity in the serum and cerebral spinal fluid for TSHA-101\n\n\nCurrent program status and anticipated next steps\n\n\nTSHA-120 in Giant Axonal Neuropathy (GAN)\n\n\nClinical safety and efficacy data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg\n\n\nUpdate on long-term clinical safety and efficacy data for the 1.2x1014 and 1.8x1014 total vg doses of TSHA-120\n\n\nOverview of global regulatory and commercialization strategy\n\n\nThe links to the webcasts and dial-in instructions for the conference calls will be available through the “Events & Media” section of the Taysha corporate website. Archived versions of the events will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the ...